Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-17), Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio is -2.15.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Tibet Rhodiola Pharmaceutical Holding Co 1-Year Sharpe Ratio Related Terms
SHSE:600211 vs ZTS: 1-Year Sharpe Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co 1-Year Sharpe Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio falls into.
Tibet Rhodiola Pharmaceutical Holding Co 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a 1-Year Sharpe Ratio of -2.15 as of Sep. 17, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio too high?
Tibet Rhodiola Pharmaceutical Holding Co's current 1-Year Sharpe Ratio is -2.15. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio compare to ZTS?
Tibet Rhodiola Pharmaceutical Holding Co's 1-Year Sharpe Ratio of -2.15 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current 1-Year Sharpe Ratio is -2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥39.80, compared to a current price of ¥35.77 — trading 10.1% below its estimated fair value. The current 1-Year Sharpe Ratio is -2.15. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current 1-Year Sharpe Ratio is -2.15 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥35.77 is trading 10.1% below its estimated GF Value™ of ¥39.80.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Modestly Undervalued.
Key valuation signals for SHSE:600211:
1-Year Sharpe Ratio: -2.15
GF Value™: ¥39.80 vs. price of ¥35.77 (10.1% below fair value)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
93GF Score
Get the complete analysis for SHSE:600211
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
